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Abstract
Rationale Most cognitive domains show only minimal im-
provement following typical or atypical antipsychotic treat-
ments in schizophrenia, and some may even worsen. One
domain that may worsen is procedural learning, an implicit
memory function relying mainly on the integrity of the fronto-
striatal system.
Objectives We investigated whether switching to atypical an-
tipsychotics would improve procedural learning and task-
related neural activation in patients on typical antipsychotics.
Furthermore, we explored the differential effects of the atyp-
ical antipsychotics risperidone and olanzapine.
Methods Thirty schizophrenia patients underwent functional
magnetic resonance imaging during a 5-min procedural
(sequence) learning task on two occasions: at baseline and
7–8 weeks later. Of 30 patients, 10 remained on typical anti-
psychotics, and 20 were switched randomly in equal numbers
to receive either olanzapine (10–20 mg) or risperidone (4–
8 mg) for 7–8 weeks.
Results At baseline, patients (all on typical antipsychotics)
showed no procedural learning. At follow-up, patients who
remained on typical antipsychotics continued to show a lack
of procedural learning, whereas those switched to atypical
antipsychotics displayed significant procedural learning (p=
0.001) and increased activation in the superior-middle frontal
gyrus, anterior cingulate and striatum (cluster-corrected
p<0.05). These neural effects were present as a linear increase
over five successive 30-s blocks of sequenced trials. A switch
to either risperidone or olanzapine resulted in comparable per-
formance but with both overlapping and distinct task-related
activations.
Conclusions Atypical antipsychotics restore procedural learn-
ing deficits and associated neural activity in schizophrenia.
Furthermore, different atypical antipsychotics produce idio-
syncratic task-related neural activations, and this specificity
may contribute to their differential long-term clinical profiles.
Keywords Sequencelearning .Striatum .Anteriorcingulate .
Typical antipsychotics . Atypical antipsychotics
Introduction
Schizophrenia is a complex neurobiological disorder thought
to arise from a dysregulation of multiple neurotransmitters
including the dopaminergic, glutamatergic and serotonergic
systems (Coyle 2006; Davis et al. 1991; Geyer and
Vollenweider 2008; Howes and Kapur 2009; Javitt and
Zukin 1991; van Rossum 1966). In addition to the core symp-
toms that form the diagnostic criteria, cognitive impairment
has been increasingly described as a prominent feature of
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schizophrenia that should be a target for treatment (Carter and
Barch 2007), given its relationship with poor functional out-
come and no established treatment so far (Harvey and Bowie
2012).
Existing pharmacological treatments include typical anti-
psychotics and, more recently, atypical antipsychotics. Typical
antipsychotics, such as fluphenazine, haloperidol and chlor-
promazine, may alleviate psychotic symptoms through the
blockade of dopamine D2 receptors in the striatum (Abi-
Dargham 2004; Laruelle and Abi-Dargham 1999; Peroutka
and Synder 1980). Commonly prescribed atypical antipsy-
chotics such as risperidone and olanzapine act on multiple
neurotransmitter systems (Kapur et al. 1998; Nord and Farde
2011). Risperidone has high affinity for both serotonin 2A
receptor (5-HT2A) and dopamine D2 receptors and modest
affinity for histamine and alpha-2 (α2) adrenergic receptors
(Leysen et al. 1994). Olanzapine has high affinity for 5-
HT2A and moderate affinity for D2, muscarinic M1–4, α1–2
and histamine H1 receptors (Arnt and Skarsfeldt 1998).
Furthermore, most atypical antipsychotics occupy D2 recep-
tors only transiently and dissociate rapidly to allow normal
dopamine neurotransmission (Seeman 2002).
Although antipsychotics were synthesised primarily to at-
tenuate psychotic symptoms, their clinical benefits and/or side
effects may extend to cognitive performance, and this needs to
be examined with specific cognitive paradigms on both the
behavioural and the neural level (Honey and Bullmore 2004).
The use of atypical antipsychotics has been reported to allevi-
ate cognitive impairment, at least to some degree (Woodward
et al. 2005), although studies comparing the effects of typical
and atypical studies have been less conclusive (Carpenter and
Conley 2007; Green et al. 2002; Keefe et al. 2007b; Meltzer
2004). While it is desirable that patients demonstrate general-
ised cognitive improvement, there is also a need to find out
whether any of the specific cognitive deficits result from, or
become exaggerated by, antipsychotic treatments (Heinrichs
2007; Hill et al. 2010).
Due to the multi-factorial nature of most traditional neuro-
psychological tests, they offer limited sensitivity to specific
cognitive changes induced by antipsychotics (Carter and
Barch 2007). Procedural learning (PL), which refers to the
gradual acquisition of skills through repeated exposure of a
specific rule-governed activity (Cohen and Squire 1980), may
provide a useful measure in this context. There is consistent
evidence that PL is sensitive to dopaminergic changes, partic-
ularly in the striatum (Foerde and Shohamy 2011). The func-
tional integrity of the striatum has been shown to be critical for
PL particularly when assessed using the serial reaction time
task (SRTT) or one of its variants (Doyon et al. 1998;
Knopman and Nissen 1991; Nissen and Bullemer 1987;
Rauch et al. 1997). SRTT is a visuospatial tracking task in
which participants gradually acquire the pattern of repeating
sequences amongst embedded random blocks without
developing explicit awareness of their learning (Howard and
Howard 1997). The learning of sequences results in faster
reaction time (RT) for the sequence trials compared to the
random trials, reflecting PL.
A meta-analysis revealed a moderate degree of impairment
in PL on the SRTT in patients with schizophrenia relative to
controls with a pooled effect size of 0.51 (Siegert et al. 2008).
The studies, however, varied in medication and patient char-
acteristics. The potential influence of antipsychotics on SRTT
performance is indicated by healthy volunteer studies where
otherwise normal performance is compromised by acute ad-
ministration of haloperidol (Kumari et al. 1997) and chlor-
promazine (Danion et al. 1992) but enhanced by the indirect
dopamine agonist d-amphetamine (Kumari et al. 1997).
Absence of PL on the SRTT has been observed in patients
on typical antipsychotics (Kumari et al. 2002) but not when
they are on atypical antipsychotics (Kumari et al. 2008;
Stevens et al. 2002). Medication-naïve first-episode patients,
and recent-onset patients with minimal prior exposure to an-
tipsychotics, show lower learning profiles and larger inter-trial
fluctuations, but no robust impairment in SRTT performance
(Kumari et al. 2008; Purdon et al. 2011).
Parallel to these behavioural findings, there is evidence
from a single-photon emission computed tomography
(SPECT) study that PL deficits induced by haloperidol may
be dopaminergically mediated in the striatum (Paquet et al.
2004). Functional magnetic resonance imaging (fMRI) studies
implementing variants of the SRTT have repeatedly shown
aberrant fronto-striatal activations in schizophrenia relative
to healthy groups (Kumari et al. 2008; Kumari et al. 2002;
Purdon et al. 2011; Reiss et al. 2006; Zedkova et al. 2006).
Patients on typical antipsychotics show fronto-striatal activa-
tion deficits (Kumari et al. 2002), whereas those on
ziprasidone (Kumari et al. 2008) and unmedicated first-
episode patients show activation patterns broadly similar to
that of healthy controls (Purdon et al. 2011). It is thus likely
that the use of typical antipsychotics gives rise to commonly
observed PL deficits, possibly in addition to an underlying
neural abnormality affecting many cognitive functions in
schizophrenia. No study has yet investigated the neural chang-
es accompanying the effects of switching from typical to atyp-
ical antipsychotics in PL on the SRRT in schizophrenia pa-
tients. Investigating changes following a switch from typical
to atypical treatment can not only clarify the impact of typical
and atypical antipsychotic treatment on PL but also provide
new insights into the differential neural effects of atypical
antipsychotics.
The primary aim of this study was to apply fMRI in a
longitudinal within-subjects design (pre- and post-) to detect
changes in the blood-oxygen-level-dependent (BOLD) re-
sponse during a PL task (SRTT) following a switch to one
of two atypical antipsychotics, risperidone and olanzapine,
in patients previously on stable doses of typical
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antipsychotics. Risperidone and olanzapine were chosen over
other atypical antipsychotics because they, despite both being
classified as atypical antipsychotics, have relatively distinct
pharmacological profiles (Arnt and Skarsfeldt 1998; Leysen
et al. 1994; Miyamoto et al. 2008) and are also two of the most
commonly prescribed antipsychotics to people with schizo-
phrenia. We hypothesised that the substitution of atypical for
typical antipsychotics would be associated with improved PL
and restored activation of neural systems that subserve PL in
healthy people. In addition, considering the different receptor
profiles of atypical antipsychotics (Miyamoto et al. 2008),
possible differences in PL and associated neural patterns be-
tween olanzapine and risperidone were explored.
Method
Participants and design
Thirty patients (aged 18–61 years) with a DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders, 4th
edition) diagnosis (First et al. 1996) of schizophrenia partici-
pated. All included patients were required to be (a) on stable
doses of typical antipsychotics for 6 or more weeks, (b) free
from illicit drugs (confirmed with urine analysis), (c) strongly
right-handed as determined using the Edinburgh Handedness
Inventory (Oldfield 1971) and (d) able to provide written in-
formed consent. Patients entering the study were examined
clinically to ensure compliance with the inclusion and exclu-
sion criteria.
The study was a single-centre, open-label study, with
blinded ratings. Within 1 week of baseline assessment, out
of 30 patients recruited into the study, 10 were randomised
to remain on typical antipsychotics for the duration of this
study, while 20 patients were randomly allocated to receive
treatment with atypical antipsychotics olanzapine (n=10) or
risperidone (n=10). The person responsible for randomisation
was aware of the patients’ gender and age but unaware of the
results of the baseline clinical and neuroimaging results.
Starting doses for atypical antipsychotics were according to
the BSummary of product characteristics^ for each of the two
drugs: 10 mg for olanzapine and 2 mg for risperidone.
Optimal dose was achieved within 14 days, and patients were
re-assessed after having been on the optimal dose for 6 weeks.
The optimal dose range for risperidone was 4–8 mg and for
olanzapine 10–20 mg. All participants underwent fMRI dur-
ing the PL task on two occasions: at baseline and then again
7–8 weeks later. Severity of symptoms was rated with the
Positive and Negative Syndrome Scale (PANSS) (Kay et al.
1987) on both occasions. Predicted IQ was assessed using the
National Adult Reading test (NART) (Nelson and Willison
1991) at baseline for sample characterisation. The age of onset
of illness and the type and doses of current antipsychotic
treatment were also recorded. Data were unusable due to mo-
tion artefacts or image acquisition failures at baseline or
follow-up for one patient of each of the risperidone and
olanzapine groups and for two patients of the typical group.
In addition, one patient of the risperidone group did not pro-
vide behavioural data (failed to press the button on most trials)
during fMRI, and one patient of each of the olanzapine and
risperidone groups did not attend their follow-up scan. The
final sample thus comprised 23 patients: 8 on typical (at base-
line, three on flupenthixol decanoate, four on zuclopenthixol
decanoate and one on fluphenazine decanoate) and 15 on
atypical antipsychotics [seven risperidone (at baseline, two
on flupenthixol decanoate, three on zuclopenthixol decanoate,
one on fluphenazine decanoate and one on trifluoperazine),
eight olanzapine (at baseline, three on flupenthixol decanoate,
two on zuclopenthixol decanoate, two on fluphenazine
decanoate and one on sulpiride)] (Table 1).
The study procedures were approved by the ethics commit-
tee of the Institute of Psychiatry and Maudsley Hospital,
London. The participants provided written informed consent
after the methods and procedure had been discussed with
them.
Experimental design and procedure
This study used the same PL task, i.e. a 5-min sequence learn-
ing task in a blocked periodic AB design, as used in a number
of previous studies (Ettinger et al. 2013; Kumari et al. 2008;
Kumari et al. 2002). Briefly stated, the task consisted of two
30-s alternating conditions: blocks of random trials (control
condition) and blocks of pattern trials (experimental condi-
tion). In total, there were five 30-s random and five 30-s pat-
tern conditions. Participants were presented with a white tar-
get stimulus (an asterisk) projected on to a black screen via a
prismatic mirror fitted in the radiofrequency head coil as they
lay in the scanner. The screen was divided into four equal
quadrants by two intersecting white lines, and the target
moved between these four locations on the screen.
For the pattern condition, the target movements were pre-
dictable for 75 % of cases, i.e. stimulus locations were deter-
mined following three specific rules: (1) a horizontal target
movement was followed by a vertical target movement, (2) a
vertical target movement was followed by a diagonal target
movement and (3) a diagonal target movement was followed
by a horizontal movement. The fourth movement of the target
during the pattern condition was determined randomly, which
then was followed by the abovementioned three specific rules.
Participants were required to follow each target movement
with their right hand as fast as possible using a MRI compat-
ible key pad with four keys, each key corresponding to one of
the four quadrants. The movement of the target was initiated
by the participants’ touching of the target key. RTs were re-
corded on-line. Participants were not told about the
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predetermined sequence during the pattern condition, and the
beginning of random and pattern condition was not marked in
any way. Prior to scanning, all participants underwent a prac-
tice session during which they practiced on five 30-s random
and five 30-s pattern condition, both alternated with 30-s rest
periods.
Image acquisition
Echoplanar MR brain images were acquired using a 1.5 T GE
Signa system (General Electric, Milwaukee, WI, USA) at the
Maudsley Hospital, London. Daily quality assurance was car-
ried out to ensure high signal-to-ghost ratio, high signal-to-
noise ratio and excellent temporal stability using an automated
quality control procedure (Simmons et al. 1999). A quadrature
birdcage head coil was used for radio frequency transmission
and reception. In each of 16 near-axial, non-contiguous planes
parallel to the intercommissural (AC-PC) plane, 100 T2*-
weighted MR images depicting blood oxygenation level-
dependent (BOLD) contrast (Ogawa et al. 1990) were
acquired over the 5 minute experiment with echo time
(TE)=40 ms, repetition time (TR)=3 s, in-plane resolu-
tion=3.1 mm, slice thickness=7.0 mm, and interslice
gap=0.7 mm. Head movement was limited by foam
padding within the head coil and a restraining band
across the forehead. At the same session, a high-
resolution 3-D inversion recovery prepared spoiled
GRASS pulse sequence was used to acquire a T1-
weighted volume in the axial plane (TR=12.2 ms,
TE=5.3 ms, TI=300 ms, flip angle=20°, in-plane reso-
lution=0.94 mm, matrix dimensions 256×256), yielding
124 contiguous slices of 1.5 mm thickness.
Data analysis
All demographic, clinical and behavioural measures were
analysed using SPSS version 22.00 (SPSS Inc., Chicago, IL
USA). Effect sizes, where reported, are partial eta squared
(i.e., the proportion of variance associated with a factor).
The α-level of significance (two-tailed) was set at p<0.05
unless indicated otherwise.
Demographic and clinical measures
Typical and atypical antipsychotic groups were compared on
age, education and predicted IQ using one-way analysis of
variance (ANOVA). The data on positive symptoms, negative
symptoms, general psychopathology and total PANSS scores
were analysed (separately) with a 2 (typical, atypical) × 2
(baseline, follow-up) repeated-measures ANOVA. Further,
one-way ANOVAs were conducted to compare the two atyp-
ical antipsychotic subgroups (risperidone, olanazapine) on
age, education and predicted IQ and 2 (risperidone,
olanzapine) × 2 (baseline, follow-up) repeated-measures
ANOVAs to examine changes in positive symptoms, negative
symptoms, general psychopathology and total PANSS scores.
Task performance
To examine group differences at baseline and follow-up, mean
RTs to blocks of random and pattern trials at baseline and
follow-up were subjected to a four-way group (2: typical,
atypical) × occasion (2: baseline, follow-up) × trial type (2:
random, pattern) × block (5: five 30-s blocks of random and
pattern trials) ANOVAwith group as a between-subjects fac-
tor, and occasion, trial type and block as within-subjects
Table 1 Descriptive statistics [mean, standard deviation (SD)] and analysis of variance results for demographics and clinical characteristics of patient
groups and subgroups
Typical
(n=8; 5 men)
Atypical
(n=15; 9 men)
ANOVA Atypical subgroups ANOVA
Group effect Risperidone
(n=7; 5 men)
Olanzapine
(n=8; 4 men)
Group effect
Mean (SD) Mean (SD) F(1,21) p Mean (SD) Mean (SD) F(1,13) p
Age (years) 46.00 (9.81) 38.60 (15.28) 1.52 0.22 35.57 (13.73) 41.25 (16.97) 0.50 0.49
Education (years) 11.25 (3.69) 12.73 (3.61) 0.87 0.36 12.29 (3.30) 13.13 (4.05) 0.19 0.67
Predicted (NART) IQ 96.37 (16.31) 103.33 (14.39) 1.11 0.30 100.57 (16.35) 105.75 (13.06) 0.47 0.51
Age at illness onset (years) 23.43 (5.62) 25.13 (10.66) 0.16 0.70 20.71 (3.90) 29.00 (13.33) 2.46 0.14
Duration of illness (years) 20.43 (9.88) 13.47 (12.75) 1.61 0.22 14.86 (14.75) 12.25 (11.63) 0.15 0.71
Antipsychotic dose in
chlorpromazine
equivalents (mg)
220.84 (146.04) 267.86a (251.62) 0.23b 0.64 314.29 (337.53) 221.43c (134.96) 0.46c 0.51
a Dose information missing for one patient
b df=1,20
c df=1,12
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factors, followed by lower-order ANOVAs and post-hoc
mean comparisons as appropriate. A further group (ris-
peridone, olanzapine) × occasion × trial type × block
ANOVA was carried out to explore possible differences
between different atypical antipsychotics, followed by
lower-order ANOVAs and post-hoc mean comparisons.
Finally, we examined potential associations across pa-
tients, between age, illness duration and symptom levels
and PL scores at baseline and follow-up using Pearson’s
correlations.
fMRI
Data were analysed using statistical parametric mapping soft-
ware (SPM8; http://www.fil.ion.ucl.ac.uk/spm) running in
MATLAB version 7.14 (The Math Works Inc).
Image preprocessing
For each participant, the 100-volume functional time se-
ries were realigned to the first volume, corrected for mo-
tion artefacts, normalised to the Montreal Neurological
Institute echo-planar imaging template, smoothed with
an 8-mm full-width at half-maximum Gaussian filter and
band-pass-filtered.
Models and statistical inferences
fMRI data were analysed using a two-stage random-ef-
fects procedure (Friston et al. 1999). The first stage
identified subject-specific task-related activations rele-
vant to pattern trials (experimental condition) over the
entire session as well as linear increases and decreases
in activity over the five blocks of pattern trials. Random
trials (control condition) served as the implicit baseline.
The contrast images were obtained by using a boxcar
design for each 30-s epoch convolved with the hemo-
dynamic response function. Motion parameters obtained
from the realignment pre-processing step were included
as covariates at this stage. In the second stage of anal-
ysis, the resulting maps were used to establish task-
related activations across subject-specific images using
one-sample t-tests for each group (typical, atypical; ris-
peridone, olanzapine) at baseline and follow-up.
Significance was assessed with correction for multiple
comparisons at the cluster level (p<0.01 corrected).
The pattern>random contrast revealed insufficient acti-
vations at the corrected level in all analyses (thus not
reported hereafter). Further described analyses were con-
ducted in contrasts with linear increases and decreases
in activity over the five blocks of pattern trials.
Significant changes from baseline to follow-up in atyp-
ical antipsychotic group were examined with group
(typical, atypical) × occasion (baseline, follow-up)
SPM ANOVA, followed by paired t-tests separately in
the typical and atypical groups. We further explored the
regions that were significantly active at follow-up fol-
lowing a switch to risperidone or olanzapine (separately)
using paired t-tests. Significance was assessed using a
correction for multiple comparisons at the cluster level
(p<0.05) with a height threshold of p=0.01 for
baseline-to-follow-up activation changes in the typical
and atypical groups and p=0.05 (to accommodate small-
er Ns and the exploratory nature of the analyses) in the
risperidone and olanzapine subgroups.
Results
Demographic and clinical measures
Age, level of education, illness duration, age of onset and the
dose of antipsychotic medication at baseline did not differ
significantly between the typical and atypical antipsychotics
group or between the two atypical antipsychotic subgroups
(risperidone, olanzapine) (Table 1).
The change in symptom levels (from baseline to
follow-up) was not significant for typical or atypical
groups or for either of the two atypical antipsychotic sub-
groups (Table 2; all p values >0.05 for all group, occasion
and group × occasion effects).
Task performance
The four-way repeated-measures ANOVA (group × occasion ×
trial type × block) revealed a significant main effect of block
[F(4,84)=4.76, p =0.008, ηρ2=0.18] and a significant interac-
tion between occasion × trial type [F(1,21)=6.84, p =0.02,
ηρ2=0.25]. The group × trial type × occasion interaction failed
to attain formal statistical significance (with small N/group),
but it had a moderate effect size [F(1,21)=2.51, p=0.13,
ηρ2=0.11], and the possible effects of typical and atypical an-
tipsychotics on PL were explored to inform our hypotheses as
noted below.
The three-way repeated-measures ANOVA (group × trial
type × block) on baseline data revealed non-significant effects
involving group, trial type × block [trial type, F(1,21)=0.26,
p=0.62, ηρ2=0.01; block × trial type, F(1,21)=0.04, p =0.85,
ηρ2=0.002; trial type × group, F(1,21)=0.04, p=0.85, ηρ2=
0.002], confirming no difference between RTs to random and
pattern trials during any of the blocks in typical or atypical
antipsychotics groups at baseline (when all patients were on
typical antipsychotics). There was only a main effect of block
[F(4,84)=3.60, p=0.03, ηρ2=0.15] with a linear effect [F(1,
21)=5.52, p=0.029, ηρ2=0.21], indicating a reduction in RTs
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from block 1 to block 5 (of both random and pattern trials)
across all patients at baseline (Table 3).
The three-way repeated-measures ANOVA (group × trial
type × block) on follow-up data showed a significant main
effect of trial type [F(1,21) =8.65, p=0.008, ηρ2=0.29] and
importantly a significant trial type × group (typical, atypical)
interaction [F(1,21)=5.77, p=0.03, ηρ2=0.22]. Separate anal-
ysis of typical and atypical group confirmed no effect of trial
type in the typical group [F(1,7)=0.17, p=0.70, ηρ2=0.02]
but a strong main effect of trial type in the atypical group
[F(1,14)=17.53, p =0.001, ηρ2=0.56], showing faster RTs
over pattern trials relative to random trials (Table 3; Fig. 1).
A significant main effect of block [F(4,84)=2.95, p=0.05,
ηρ2=0.12] with a linear decrease in RT over the five blocks
of trials [F(1,21)=6.09, p=0.02, ηρ2=0.22] was also present,
but there was no significant interaction involving the block
factor (p >0.05).
The three-way repeated-measures ANOVA (occasion × tri-
al type × block) for the typical antipsychotic group yielded no
significant effects of trial type [F(1,7)=0.01, p=0.91 , ηρ2=
0.002], occasion [F(1,7)=1.14, p=0.32, ηρ2=0.14] or occa-
sion × trial type [F(1,7)=0.29, p=0.61, ηρ2=0.04], indicating
that patients who remained on typical antipsychotics did not
show RT reduction to pattern trials relative to random trials at
baseline or follow-up. The three-way repeated-measures
ANOVA (occasion × trial type × block) for the atypical group
showed a significant main effect of trial type [F(1,14)=5.30,
p=0.04, ηρ2=0.27] and a significant interaction effect of oc-
casion × trial type [F(1,14)=6.08, p=0.001, ηρ2=0.53].
Follow-up of this (occasion × trial type) interaction showed
no effect of trial type or block at baseline (p values >0.20) but
a highly significant main effect of trial type [F(1,14)=17.54,
p=0.001, ηρ2=0.56], showing much faster RTs during pattern
trials than random trials over the entire experiment (random
trials: mean=0.33 s, SEM=0.39; pattern trials: mean=0.298 s,
SEM=0.034) at follow-up in this group (Table 3).
Exploration of the atypical subgroups (risperidone,
olanzapine) revealed comparable reduction in RTs to pattern
trials relative to random trials at follow-up as demonstrated by
a significant occasion × trial type interaction [F(1,13)=14.86,
p=0.002, ηρ2=0.53], but no significant group [F(1,13)=3.06,
p=0.10, ηρ2=0.19], group × trial type [F(1,13)=0.58, p=
0.46, ηρ2=0.04] or group × occasion × trial type effect [F(1,
13)=0.20, p =0.66, ηρ2=0.01].
Age and illness duration did not correlate with PL scores at
baseline (age: r=−0.12, p=0.58; illness duration: r=0.10, p=
0.66) or follow-up (age: r=−0.03, p=0.88; illness duration: r=
0.07, p=0.76). PANSS symptom ratings and PL scores were
also not significantly correlated at baseline (positive symp-
toms: r=−0.19, p=0.30; negative symptoms: r=−0.08, p=
0.69; general psychopathology: r=−0.16, p=0.45; total
symptoms: r=−0.04, p=0.85) or follow-up (positive symp-
toms: r=−0.09, p=0.68; negative symptoms: r=−0.14, p=Ta
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0.52; general psychopathology: r=−0.19, p=0.39; total symp-
toms: r=−0.17, p=0.45).
fMRI
Generic task-related activations
Baseline In line with the behavioural results, there were no
significant task-related activations in typical or atypical
groups when patients were all on typical antipsychotics.
Follow-up Patients who remained on typical antipsychotics
did not show any significant activation changes also at follow-
up. In those who were switched to atypical antipsychotics,
activity in the superior-middle frontal and anterior cingulate
increased linearly over the five blocks of pattern trials
(Table 4). When explored separately in the risperidone and
olanzapine subgroups, the risperidone subgroup showed a sig-
nificant activity increase over the five blocks in the lentiform
nucleus extending to the insula (Table 4). The olanzapine sub-
group showed a significant activity increase over the five
blocks in the caudate extending to the anterior cingulate and
precentral gyrus (Table 4). No area showed activation de-
creases over the five blocks of pattern trials.
Activation changes from baseline to follow-up
There were no activation increases or decreases (at the
corrected or uncorrected cluster level) from baseline to
follow-up in those who remained on typical antipsychotics.
Following a switch to atypical antipsychotics, increased acti-
vation, relative to baseline, was seen in one cluster in the
bilateral superior frontal gyrus extending to the inferior frontal
gyrus and in another cluster in the left anterior cingulate,
extending to the right putamen and bilateral caudate
(Table 5; Fig. 2a); no area showed a significant decrease in
activity from baseline to follow-up.
During exploration of the two atypical groups separately,
the risperidone group showed activation increases in a large
cluster in the posterior cingulate, extending to the left middle
occipital gyrus, bilateral paracentral lobule and left precuneus
(Table 5). Additional activation increases, at the uncorrected
cluster level, were found in the putamen (bilaterally) extend-
ing to the left caudate, bilateral insula and bilateral cingulate
gyrus; the left superior temporal gyrus extending to the left
inferior-middle frontal gyrus; the right middle temporal gyrus
extending to the right parahippocampal gyrus; and the right
superior frontal gyrus (Table 5; Fig. 2b). In the olanzapine
group, there was increased activity in the bilateral anterior
cingulate (bilateral), extending to the left precentral gyrus,
right superior and bilateral middle frontal gyrus, left insula,
bilateral caudate and left putamen (Table 5; Fig. 2c). No area
showed a significant decrease in activity from baseline to
follow-up in the risperidone or olanzapine subgroups.
Discussion
To our knowledge, this is the first longitudinal fMRI study
examining the neural effects associated with switching schizo-
phrenia patients from typical to atypical antipsychotics using a
fMRI-compatible PL task. We also explored the possible dif-
ferentiation between risperidone and olanzapine.
Behavioural findings
At baseline, patients (all on typical antipsychotics) did
not show PL (i.e. no significant difference between RTs to
Table 3 Task performance [mean, standard error of the mean (SEM)] of patient groups and sub-groups at baseline and follow-up
Typical (n=8) Atypical (n=15) Risperidone (n =7) Olanzapine (n=8)
Task performance Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Reaction time (ms) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
Block 1 Random trials 0.348 (0.075) 0.308 (0.063) 0.296 (0.055) 0.338 (0.0465) 0.230 (0.025) 0.322 (0.082) 0.355 (0.072) 0.352 (0.059)
Pattern trials 0.426 (0.089) 0.314 (0.056) 0.322 (0.065) 0.301 (0.041) 0.223 (0.017) 0.278 (0.052) 0.408 (0.099) 0.321 (0.055)
Block 2 Random trials 0.433 (0.085) 0.302 (0.055) 0.353 (0.062) 0.335 (0.040) 0.232 (0.026) 0.305 (0.058) 0.459 (0.094) 0.361 (0.055)
Pattern trials 0.447 (0.075) 0.303 (0.059) 0.308(0.055) 0.318(0.043) 0.218 (0.020) 0.296 (0.075) 0.387 (0.066) 0.337 (0.048)
Block 3 Random trials 0.430 (0.077) 0.292 (0.062) 0.319 (0.056) 0.343 (0.046) 0.218 (0.033) 0.339 (0.010) 0.407 (0.070) 0.347 (0.035)
Pattern trials 0.469 (0.091) 0.286 (0.052) 0.330 (0.067) 0.301 (0.038) 0.206 (0.027) 0.290 (0.070) 0.438 (0.082) 0.310 (0.036)
Block 4 Random trials 0.466 (0.081) 0.295 (0.052) 0.302 (0.059) 0.317 (0.038) 0.192 (0.032) 0.283 (0.059) 0.399 (0.061) 0.347 (0.037)
Pattern trials 0.448 (0.083) 0.296 (0.051) 0.314 (0.061) 0.288 (0.037) 0.197 (0.024) 0.256 (0.054) 0.416 (0.068) 0.317 (0.039)
Block 5 Random trials 0.393 (0.068) 0.267 (0.048) 0.294 (0.049) 0.316 (0.035) 0.194 (0.036) 0.300 (0.060) 0.381 (0.054) 0.330 (0.032)
Pattern trials 0.395 (0.076) 0.270 (0.047) 0.303 (0.056) 0.282 (0.0346) 0.197 (0.029) 0.254 (0.036) 0.395 (0.058) 0.307 (0.034)
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Fig. 1 aMean (+1 standard error
of the mean) procedural learning
scores (mean reaction times over
five blocks of pattern trials minus
mean reaction times over five
blocks of random trials) at
baseline and follow-up in the
group that remained on typical
antipsychotics and the group that
was switched to atypical
antipsychotics (risperidone or
olanzapine). bMean (+1 standard
error of the mean) procedural
learning scores at baseline and
follow-up in patients switched
from typical antipsychotics to
risperidone and olanzapine
Table 4 Brain areas showing significant activation increases (over block 1 to block 5 of pattern, relative to random, trials) in the atypical antipsychotics
group at follow-up
Brain region BA Side MNI coordinates Voxel T value Cluster size (voxel n) Cluster-corrected p
x y z
Atypical antipsychotics (across risperidone and olanzapine) (height threshold p=0.01)
Superior frontal gyrus 10 R 36 58 2 4.91 1259 0.016
10 R 24 60 6 3.41
10 R 24 52 16 3.10
Middle frontal gyrus 10/46 R 34 56 16 3.68
Anterior cingulate/medial frontal gyrus 32/10 R 2 54 14 3.46
Separately for risperidone and olanzapine (height threshold p=0.05)
Risperidone
Lentiforn nucleus n/a R 24 −20 −4 7.75 4496 0.001
Insula n/a R 34 24 8 7.23
Superior frontal gyrus 10 R 32 48 −2 3.48
Olanzapine
Caudate n/a R 6 2 10 4.97 5879 0.01
Anterior cingulate 24/32 R 12 32 20 4.66
Precentral gyrus 6 R 36 −2 28 4.49
BA Brodmann area, MNI Montreal Neurological Institute, R right, L left
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random and pattern trials); there was also no difference in PL
of patients who remained on typical antipsychotics and those
who were later switched to receive risperidone or olanzapine.
At follow-up, there was a difference between the typical and
atypical groups that was in accordance with our a priori hy-
potheses, with significantly faster RTs to pattern, relative to
random, trials in those on atypical (but not typical)
antipsychotics.
Table 5 Brain areas showing significant activation increases (over block 1 to block 5 of pattern, relative to random, trials) from baseline to follow-up
after a switch to atypical antipsychotics (height threshold p=0.01)
Brain region BA Side MNI coordinates Voxel T value Cluster size (voxel n) Cluster p
Following a switch to atypical antipsychotics risperidone or olanzapine (height threshold p=0.01)
Superior frontal gyrus 10 R 20 50 18 4.26 1115 0.007
10 L −22 50 6 3.39
Inferior frontal gyrus 47 R 30 34 4 3.56
10 L −40 52 6 3.27
Anterior cingulate 32 L −14 18 22 4.6 851 0.029
Putamen R 22 4 8 3.67
Caudate R 14 26 8 3.21
L −16 6 14 3.07
Separately for risperidone and olanzapine (height threshold p=0.05)
Following switch to risperidone
Posterior cingulate 30 L −16 −60 4 11.31 6037 <0.001
30 R 10 −58 18 6.14
Middle occipital gyrus 19 L −22 −68 4 7.72
Paracentral lobule 5 R 18 −40 54 7.14
5 L −6 −44 48 6.80
Precuneus 19 L −32 −78 38 6.69
Putamen n/a L −16 6 10 10.35 2029 0.002
n/a R 32 4 10 5.83
Caudate n/a L −12 12 2 5.68
Insula n/a L −34 −12 8 5.37
Cingulate gyrus 24 R 4 −10 26 5.17
24 L −2 −6 28 3.87
Anterior cingulate 32 L −2 12 26 4.24
Superior temporal gyrus 22 L −48 −16 −8 9.89 1097 0.018
Inferior frontal gyrus 47 L −46 24 0 9.73
Middle frontal gyrus 9 L −30 30 22 6.75
Middle temporal gyrus 21 R 54 −18 −16 9.91 1033 0.021
Parahippocampal gyrus 36 R 46 −32 −10 5.85
Superior frontal gyrus 10 R 18 66 18 6.12 811 0.037
Following switch to olanzapine
Anterior cingulate 32 L −14 18 22 3.84 7429 < 0.001
32 R 12 18 22 3.55
Precentral gyrus 6 L −36 −2 28 3.55
Cingulate gyrus 32 R 18 4 46 3.48
Superior frontal gyrus 6 R 2 6 58 3.45
Middle frontal gyrus 9 R 38 28 42 3.43
8 L −26 30 52 3.43
Insula 13 L −46 −2 16 3.41
Caudate L −6 4 20 3.37
R 4 6 8 3.37
Putamen L −18 18 2 3.3
Cluster p in italics: uncorrected. All others: cluster p corrected for multiple comparisons across the entire brain
BA Brodmann area, MNI Montreal Neurological Institute, R right, L left
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An aspect of the experiment deserving comment is that
although significantly faster RTs to pattern, relative to random,
trials reflect PL in the atypical group at follow-up, this difference
was present even during the very first block of trials, suggesting
that patients on atypical antipsychotics had learnt the sequence
during the first block itself, perhaps due to the practice session
conducted just prior to scanning. This was also observed earlier
in a healthy group with the same task and administration proce-
dures (Kumari et al. 2002), but it may also mean that the neural
findings of this study relate to the recall, rather than acquisition,
of implicit knowledge about the sequences.
The pattern of results obtained in the typical and atypical
antipsychotic groups at baseline and follow-up is consistent
with the finding of previous studies using SRTT (Green et al.
1997; Kumari et al. 2008; Kumari et al. 2002) and also of
those using other PL tasks (Paquet et al. 2004; Purdon et al.
2003; Scherer et al. 2004). Specifically, studies have reported
normal PL on a visual tracking task in patients on olanzapine,
but not in those on haloperidol (Paquet et al. 2004); normal PL
on a mirror drawing task was shown in those on clozapine or
risperidone, but not in those on haloperidol (Scherer et al.
2004), and preserved PL, defined as the improvement ob-
served between two blocks of five trials of the Tower of
Toronto, following 6 months of treatment with olanzapine
but a decline following the 6-month use of risperidone or
typical antipsychotics in medication-naïve patients (Purdon
et al. 2003). Atypical antipsychotic treatment-related PL
changes apparent at follow-up may at least in part represent
a functional consequence of the robust antagonism of D2 re-
ceptors in the striatum by typical antipsychotics at baseline
(Bedard et al. 1996; Kumari et al. 2002) and less so at fol-
low-up. The inconsistency of results in previous studies re-
garding risperidone use may be explained by the varying
doses of risperidone and sample characteristics in previous
studies. Risperidone, when given at doses of more than
8 mg/daily, produces an extrapyramidal symptoms profile
(Lemmens et al. 1999) and D2 blockade broadly similar to
that of typical antipsychotics (Marder and Meibach 1994).
The effects of risperidone at a given dose are also known to
be affected by illness chronicity. Maximum antipsychotic ac-
tivity occurs at 4–6 mg/day for chronic schizophrenia patients,
whereas first-episode patients respond to lower (2–5 mg/day)
doses, and in chronic patients, daily doses of up to 8 mg/day
are not associated with a greater risk of extrapyramidal symp-
toms than placebo (Foster and Goa 1998). The patients includ-
ed in our study were chronically ill, and no patient was on
more than 8 mg daily dose of risperidone (six of eight patients
on 4–6 mg/day). This may explain improved PL in
risperidone-treated patients at follow-up in our study.
Previously, it has been suggested that PL deficits may be
linked to a symptomatic state (Exner et al. 2006). However,
absent PL in the typical antipsychotic group does not seem to
be related to clinical manifestation of symptoms or attentional
difficulties since their RTs improved over successive blocks. It
is likely that task familiarity or practice contributed to RT
learning in typical antipsychotic patients since faster RT over
blocks 1 to 5 occurred only at follow-up. Patients on typical
antipsychotics have been suggested to rely on RT learning,
whilst healthy controls tend to switch from RT learning to
pattern learning towards later trials (Green et al. 1997).
Improved PL despite non-significant symptom changes at
follow-up in patients who were switched to atypical antipsy-
chotics also suggests lack of a direct relationship between PL
and symptom levels in stable schizophrenia patients.
Neural changes following a switch to atypical
antipsychotics
Typical antipsychotics use was associated with deficient task-
related activation at baseline and follow-up. This
Atypical antipsychotic group
Risperidone subgroup
Olanzapine subgroup
Z=8
Putamen
Anterior cingulate Superior frontal gyrus
Caudate
Middle 
temporal 
gyrus
Superior 
temporal 
gyrus
4
T value
a
b
c
3
2
1
Z=18 Z=22
Z=-16 Z=10
T value
10
8
6
4
2
Z=18
Z=6 Z=16 Z=22
T value
Midddle 
occipital 
gyrus
Putamen Caudate
Superior frontal gyrus
Inferior frontal gyrus
1
2
3
Anterior cingulate
Putamen
CaudateInsula
Fig. 2 a Areas of increased brain activity following atypical
antipsychotic treatment (height threshold p<0.01) in axial views with
associated MNI z coordinates. Left hemisphere is shown on the left. b,
c Areas of increased brain activity separately for atypical antipsychotic
subgroups—risperidone and olanzapine (height threshold p <0.05)
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complements our behavioural results of absent PL and repli-
cates a previous fMRI study involving male patients only
(Kumari et al. 2002). As anticipated, 6-week atypical antipsy-
chotic treatment was associated with increased activation
(over the five successive blocks of pattern trials) in the supe-
rior frontal gyrus extending to the inferior frontal gyrus and
anterior cingulate extending to the caudate and putamen.
Importantly, the areas showing activation increases following
atypical antipsychotic treatment closely resemble those shown
by healthy controls (Kumari et al. 2008; Purdon et al. 2011;
Reiss et al. 2006; Zedkova et al. 2006). It is thus possible that
the lack of PL and the lack of task-related activations at base-
line were due, at least in part, to the potent D2 blocking mech-
anism of typical antipsychotics as suggested previously
(Bedard et al. 1996; Kumari et al. 1997; Kumari et al. 2002).
Interestingly, increased activation in the superior–inferior
frontal gyrus, anterior cingulate and striatum was present as
a linear increase over five successive 30-s blocks of sequenced
trials. This observation, taken together with an earlier finding
showing that clozapine-treated patients show progressive PL
over successive trials whereas those treated with haloperidol
show a high degree of fluctuation over trials (Bedard et al.
1996), indicates that a linear contrast may be more useful in
characterising the incapacity to automate pattern learning in
typically treated patients or a better capacity to reach optimal
performance over a 5-min period in atypically treated patients.
Exploration of neural changes following a switch
to risperidone and olanzapine
When baseline-to-follow-up neural changes were explored
separately in the two atypical subgroups, partially overlapping
and idiosyncratic activation changes emerged. Despite equiv-
alent behavioural performance, the risperidone group activat-
ed regions in the posterior cingulate extending to middle oc-
cipital gyrus, paracentral lobule and precuneus followed by
non-significant activation changes in the putamen, caudate,
insula, cingulate gyrus, temporal regions and superior frontal
gyrus. Increased activity in the posterior cingulate and middle
temporal gyrus [in ziprasidone-treated individuals (Kumari
et al. 2008)] and the precuneus [in healthy controls (Kumari
et al. 2002)] has been shown to have a direct positive associ-
ation with PL magnitude. Temporal regions have been sug-
gested to play a compensatory role to overcome fronto-striatal
deficits in schizophrenia and thereby achieve comparable PL
as healthy controls (Zedkova et al. 2006). The risperidone-
treated group failed to activate the striatal regions at the
corrected level (possibly due to higher D2 blocking properties
of risperidone compared to olanzapine), further supporting
that the compensatory action of alternate regions contributed
to the observation of improved PL at follow-up in this group.
Following a switch to olanzapine, significant task-related
activation changes were detected in the anterior cingulate
extending to the precentral gyrus, superior frontal gyrus, mid-
dle frontal gyrus, insula and striatum. Activation of this neural
network is consistent with previous studies following success-
ful PL in healthy controls (Kumari et al. 2008; Kumari et al.
2002; Purdon et al. 2011; Zedkova et al. 2006). This focused
activation of PL-related regions possibly contributed to the
PL-normalising effects of olanzapine.
Limitations
First, this study is limited by unequal groups and small sample
size and subsequent lack of robust statistical power. However,
switching the same patients from typical to atypical antipsy-
chotics reduced inter-individual differences. A second limita-
tion may be the inclusion of patients on a range of oral and
depot typical antipsychotics, introducing a potential source of
heterogeneity. Previous studies have suggested that various
typical antipsychotics may have different neural and cognitive
effects depending on their potency (Abbott et al. 2011; Keefe
et al. 2007a). Future studies could include low-potency typical
antipsychotics when comparing with atypical antipsychotics.
Third, the duration of exposure to atypical antipsychotics was
short. Since PL has been shown to decline after 6 months of
treatment with risperidone but not with olanzapine (Purdon
et al. 2003), longer-term follow-up is needed for medication
to be stabilised and to help elucidate how medication-induced
changes in neural function evolve over time. Fourth, this
study, as also mentioned earlier, may have identified neural
effects associated with recall, and not acquisition, of implicit
knowledge about the sequences. Further research with more
sophisticated analytic strategies and longer exposures (e.g.
with inclusion of the practice session and repeated presenta-
tion of the task) is required to explore this possibility. Practice
session data in all baseline and follow-up sessions were not
systematically recorded; thus, the exact effects of the practice
session on baseline or follow-up task performance could not
be examined in the present study. Further research could also
use different experimental designs to separate the RT (fine
motor) and sequence learning (cognitive) components, the
latter of which is more likely to involve higher cortical brain
regions, and include an additional group of treatment-naïve
schizophrenia patients to clarify the effects of typical antipsy-
chotics on PL and related brain activations. Fifth, given the
dose-dependent actions of atypical antipsychotics on dopa-
mine D2 receptors and in addition on many other receptors
(Arnt and Skarsfeldt 1998; Foster and Goa 1998) and the
absence of receptor imaging data in this study, our suggestion
of reduced antagonism of D2 receptors at follow-up (relative
to baseline) in those switched to risperidone or olanzapine as
the potential mechanism for improved PL seen in this study
remains speculative and requires further study. Finally, al-
though not directly relevant to the aims of this study, it would
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have been informative to study a matched healthy control
group over two occasions and establish healthy activation pat-
terns in a test–retest design.
Conclusions
Our findings of absent PL and deficient task-related activation
at baseline and follow-up in the typical antipsychotic group
and normalisation of PL and restoration of PL-related regions
following a switch to atypical antipsychotics suggest that PL
deficits may be secondary to treatment with typical antipsy-
chotics via potent D2 blocking mechanism. Substituting ris-
peridone and olanzapine may have different effects on brain
function, and this in turn may relate to the differences in their
receptor binding long-term clinical profiles. The present find-
ings suggest that SRTT combined with fMRI may provide a
useful biomarker for exploring the effects of medication on PL
and emphasise the importance of considering medication sta-
tus and antipsychotic type in neuroimaging studies.
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